An interventional study of Saline-Enhanced Radiofrequency Catheter and Ablation System in Tachycardia, Ventricular, sponsored by Thermedical, Inc.. Completed at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-28.
Sponsored by Thermedical, Inc. · Not applicable, Interventional, and Treatment
The purpose of this study is to demonstrate the technical feasibility of the SERF Catheter and SERF Cardiac Ablation System to eliminate or control ventricular tachycardia (VT)
623 studies on the registry are indexed under Tachycardia; 81 are open to participants now.
This study's enrollment of 25 is below the median of 64 across 379 interventional studies indexed under Tachycardia.
Browse Tachycardia studies →Thermedical, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
Device: Saline-Enhanced Radiofrequency Catheter and Ablation System
Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
Also known as: SERF Ablation System and Durablate™ Ablation Catheter
Serious Adverse Events that are potentially device-related
Time frame: Within 30 days of ablation
Major Adverse Cardiac Events
MACE will be accessed from time of ablation to time of discharge from hospital following the ablation (generally within 2 days of ablation procedure).
Time frame: Within 2 days after ablation procedure
Non-inducibility of clinical ventricular tachycardia (VT) and/or elimination of clinically relevant scar or channels
Time frame: At completion of ablation procedure
Intraprocedural non-inducibility and/or scar homogenization of target VT
Time frame: At completion of ablation procedure
Elimination of the target VT and/or reduction in number of VT episodes
Time frame: Within first 6 months of ablation procedure
Plan to share: Undecided
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Thermedical, Inc.